Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenue	$ 570	$ 275
Costs and expenses:
Research and development	16,574	13,979
General and administrative	6,881	6,202
Total costs and expenses	23,455	20,181
Loss from operations	(22,885)	(19,906)
Interest expense	(1)	(2)
Financing costs - warrant liabilities	(383)
Change in fair value of warrant liabilities	2,106
Other income (expense), net	912	93
Loss before provision for income taxes	(20,251)	(19,815)
Provision for income taxes	0	0
Net loss attributable to Vaccinex, Inc. common stockholders	(20,251)	(19,815)
Comprehensive loss	$ (20,251)	$ (19,815)
Net loss per share attributable to Vaccinex, Inc. common stockholders, basic	$ (43.68)	$ (98.05)
Net loss per share attributable to Vaccinex, Inc. common stockholders, diluted	$ (43.68)	$ (98.05)
Weighted-average shares used in computing net loss per share attributable to Vaccinex, Inc. common stockholders, basic	463,653	202,082
Weighted-average shares used in computing net loss per share attributable toVaccinex, Inc. common stockholders, diluted	463,653	202,082